Trials / Completed
CompletedNCT03050229
SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 174 (actual)
- Sponsor
- Jichi Medical University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To explore the beneficial effects of 'empagliflozin + ARB' in comparison with 'placebo + ARB' on the reduction of nocturnal blood pressure in T2DM with hypertension
Detailed description
The study consists of a 8-week run-in period and a 12-week treatment period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | Empagliflozin 10mg/day once daily before or after breakfast |
| DRUG | Placebo | Placebo once daily before or after breakfast |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-10-01
- Completion
- 2018-03-01
- First posted
- 2017-02-10
- Last updated
- 2018-03-27
Locations
12 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03050229. Inclusion in this directory is not an endorsement.